RecruitingPhase 2/3

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

United States610 participantsStarted 2025-06-12

Plain-language summary

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of open-angle glaucoma or ocular hypertension in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye

What they're measuring

Intraocular pressure (IOP)

Timeframe: 3 months

Trial details

NCT IDNCT07075718

SponsorGlaukos Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-03

Contact for this trial

Study Director

949-739-8749 ClinicalResearch@glaukos.com

View on ClinicalTrials.gov More Glaucoma trials